Trellus Health
plc
("Trellus
Health" or the "Company")
Grant of Share
Options
LONDON, U.K. AND NEW YORK, U.S. (5 March 2024).
Trellus Health plc (AIM: TRLS), a health services
company delivering innovative, scientifically validated programs
and technologies that facilitate the comprehensive management of
chronic conditions, improving health outcomes whilst managing costs
of care, announces that the Board has
granted options over a total of 2,000,000 ordinary shares of
£0.0006 each in the capital of the Company (the "Share Options") to
the following PDMRs:
|
Name
|
Position
|
Options granted
|
|
|
|
|
|
Marla Dubinsky
|
Chief Executive Officer
|
500,000
|
|
Joy Bessenger
|
Chief Financial Officer
(non-Director)
|
1,500,000
|
The Share Options, which have been
issued in line with the Company's existing share option plan, have
an exercise price of 14p per ordinary share.
Both of these options would vest and
become exercisable as to one third in 12 months of the grant date
and in eight (8) equal quarterly instalments thereafter, of which
the first instalment shall vest three months after the first
anniversary of the grant date and the eighth shall vest 36 months
after the grant date, save that the option shall be exercisable in
full in connection with a Change of Control.
For
further information please contact:
|
Trellus Health plc
|
https://trellushealth.com/
|
|
Dr. Marla Dubinsky, CEO and
Co-Founder
|
Via Walbrook
PR
|
|
Dr. Daniel Mahony,
Chairman
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser and
Broker)
|
Tel: +44 (0)20 7496
3000
|
|
Aubrey Powell / Jen
Boorer
|
|
|
|
|
|
Walbrook PR
|
Tel: +44 (0)20 7933
8780 or trellus@walbrookpr.com
|
|
Paul McManus / Sam Allen / Phillip
Marriage
|
Mob: +44
(0)7980 541 893 / (0)7502 558 258/ (0)7867
984 082
|
|
|
| |
This announcement contains inside information for the purposes
of the retained UK version of the EU Market Abuse Regulation (EU)
596/2014 ("UK MAR").
About Trellus Health plc (www.trellushealth.com)
Trellus Health (AIM: TRLS) is the
first clinically-proven digital health company targeting the
intersection of chronic illness and mental health. Trellus Health
integrates its proprietary resilience-based methodology with the
technology, tools, and expert coaching and educator team to deliver
Trellus Elevate™, a whole-person technology-enhanced experience
that empowers individuals to master their health and results in
relieving disease burden, building self-management skills and
promoting positive health behaviours that improve outcomes and
enables thriving in the face of a chronic condition.
The Company's proven whole person
approach recognizes the interconnectedness of various aspects of a
person's life and aims to address the whole spectrum of factors
that influence behaviour. By looking at all aspects of an
individual, the Company not only treats symptoms but promotes
comprehensive well-being and human flourishing. Trellus Health
addresses behavior change with a combination of technology,
interventions, education, and support mechanisms designed to
empower individuals to take an active role in managing and
mastering their health and sustain positive lifestyle modifications
and resilient health-related behaviours. By bringing these
components together, Trellus Elevate™ promotes positive change in
individual behaviours and enhancing provider quality metrics in a
way that aligns with value-based care. Our approach enables better
health outcomes in a member-centric, personalized and holistic
comprehensive solution.
The Company was founded by Mount
Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD,
both experts at treating and healing both the physical and
emotional impacts of IBD and IBS and have been innovators for whole
person healthcare for a combined 50 years.
The Company is initially focusing on
chronic costly GI conditions that have high mental health burden,
like inflammatory bowel disease ("IBD") which includes the chronic
incurable conditions of Crohn's Disease and ulcerative colitis and
Irritable Bowel Syndrome ("IBS"). Given the common emotional and
mental health struggles often experienced by individuals suffering
from a variety of chronic conditions, Trellus Health considers its
approach to be agnostic, having potential utility and demand across
many conditions.
The Trellus Elevate™ program
incorporates the GRITT™ methodology and learnings on resilience
from clinical research and practice conducted at the Mount Sinai
IBD Center for more than seven years. This proprietary,
resilience-driven methodology has been scientifically validated to
demonstrate meaningful improvements in patient outcomes, 71%
reduction in Emergency Department (A&E) visits, and 94%
reduction in unplanned hospitalisations, which the directors of the
Company believe indicates the potential for significant cost
savings for healthcare payers and health systems. Patients with IBD
managed with the proprietary resilience methodology also
experienced a 49% reduction in required opioid use and a 73%
reduction in corticosteroid use 12 months following starting the
program which is a major indicator of improved health
outcomes1.
Shares in Trellus Health were
admitted to trading on AIM in May 2021, under the ticker TRLS. For
more information on Trellus Health, visit:
www.trellushealth.com
1 Source:
https://www.sciencedirect.com/science/article/pii/S1542356521012258)
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Marla Dubinsky
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
(Director)
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Trellus Health plc
|
|
b)
|
LEI
|
2138002FHWJSR8YKP295
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Options over ordinary shares of
£0.0006 each in the Company
|
|
|
|
|
Identification code
|
GB00BNNFM402
|
|
|
|
|
b)
|
Nature of the transaction
|
Grant of options over
shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£0.14
|
500,000
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
N/A
|
|
|
|
|
- Price
|
N/A
|
|
|
|
|
e)
|
Date of the transaction
|
4 March 2024
|
|
f)
|
Place of the transaction
|
Outside of trading venue - off
market
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Joy Bessenger
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer (Not a
director)
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Trellus Health plc
|
|
b)
|
LEI
|
2138002FHWJSR8YKP295
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Options over ordinary shares of
£0.0006 each in the Company
|
|
|
|
|
Identification code
|
GB00BNNFM402
|
|
|
|
|
b)
|
Nature of the transaction
|
Grant of options over
shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£0.14
|
1,500,000
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
N/A
|
|
|
|
|
- Price
|
N/A
|
|
|
|
|
e)
|
Date of the transaction
|
4 March 2024
|
|
f)
|
Place of the transaction
|
Outside of trading venue - off
market
|